Related by context. All words. (Click for frequent words.) 86 pivotal Phase III 83 Phase III 82 Phase III clinical trials 82 Phase IIb 81 Phase IIb clinical 80 Phase 2b clinical 79 Phase IIb trial 79 Phase IIa clinical 79 Phase Ib 79 clinical trial 79 Phase 2a clinical 79 phase IIb 78 Phase 2b study 78 phase IIb clinical 78 pivotal Phase 77 Phase IIa 77 Phase III trials 77 phase IIa 77 Phase 1b clinical 76 Phase 2b 76 Phase III pivotal 76 phase IIa clinical 76 Phase Ib clinical 75 Phase 2a 75 Phase IIa trial 75 Phase 2b trial 75 Phase 2a trial 74 confirmatory Phase III 74 Phase II 73 randomized Phase 73 Phase 1b 73 clinical trials 72 Phase 1b trial 72 Phase IIIb clinical 71 dose escalation trial 71 Phase Ia 71 phase 2a 71 placebo controlled Phase 70 confirmatory Phase 3 70 Phase 1a 70 registrational 70 Phase #b/#a 70 phase Ib 70 Phase IIIb 69 multiple ascending dose 69 Phase Ib study 69 phase IIb trial 69 APEX PD 69 multicenter Phase II 69 Phase IIa trials 69 Phase IIb trials 69 phase Ib clinical 69 Phase Ib II 69 placebo controlled Phase III 69 dirucotide 68 investigational drug 68 placebo controlled clinical 68 placebo controlled 68 Phase Ib clinical trials 68 preclinical 68 dose escalation study 68 multicenter clinical 67 JAK inhibitor 67 oral ridaforolimus 67 SUCCEED trial 67 multicenter Phase 67 dose escalation Phase 67 Phase 1a clinical 67 Phase IIB 67 Phase IIb clinical trials 67 Phase 2b clinical trials 66 ADVANCE PD 66 Dacogen injection 66 randomized placebo controlled 66 NO# [002] 66 single ascending dose 66 investigational compound 66 pivotal bioequivalence 66 Amrubicin 66 randomized Phase IIb 66 IIa trial 66 randomized controlled Phase 65 Corlux 65 randomized Phase III 65 Phase III randomized 65 registrational trial 65 initiate Phase 65 FOLOTYN ® 65 TG MV 65 Phenoptin 65 Omigard 65 teduglutide 65 BRIM3 65 Phase IIb kidney transplant 65 Zerenex 65 Cloretazine R VNP#M 65 dose escalation clinical 65 Asentar 65 double blind placebo 64 alvespimycin 64 randomized controlled 64 elotuzumab 64 Phase IIb III 64 Phase #b/#a clinical 64 phase IIb study 64 COMFORT II 64 randomized clinical 64 IND enabling 64 placebo controlled randomized 64 Phase IIa clinical trials 64 alvimopan 64 Phase IIIb study 64 IMA# 64 Phase III Pivotal 64 PREOS 64 Phase 64 Phase III placebo controlled 64 initiate Phase IIb 64 Phase #/#a 64 phase IIb III 64 ocrelizumab 64 Phase 2b kidney transplant 64 investigational 64 Investigational Device Exemption IDE 64 VEGF Trap 64 INCB# [001] 64 rNAPc2 64 CB2 selective receptor agonist 64 randomized double 64 subcutaneous formulation 64 multicenter Phase III 64 PRX # 64 Azedra 63 NDA submission 63 carfilzomib 63 ongoing Phase 1b 63 forodesine 63 Canvaxin 63 BLA submission 63 tanespimycin 63 lomitapide 63 AQ4N 63 Phase Ib IIa 63 Phase III confirmatory 63 viral kinetic 63 oral deforolimus 63 PEG PAL 63 EOquin 63 Cloretazine ® 63 MAA submission 63 mipomersen 63 multicenter randomized placebo controlled 63 pharmacokinetic 63 dose escalation 63 fidaxomicin Phase 3 63 ZYBRESTAT 63 Phase III Clinical Trial 63 midstage studies 63 Phase III randomized controlled 63 MIST II 63 axitinib 63 RSD# oral 63 double blinded placebo 63 Fodosine 63 multicenter randomized double 63 Urocidin 63 Alpharadin 63 tolevamer 63 TELCYTA 63 CEQ# 63 multicenter randomized Phase 63 glufosfamide 62 Aurexis 62 randomized multicenter 62 clinical pharmacology studies 62 IMGN# 62 Sulonex 62 daclizumab 62 reslizumab 62 ENDEAVOR IV 62 midstage trials 62 Phase III psoriasis 62 KNS # 62 MBP# [001] 62 pharmacokinetic PK study 62 GetGoal Phase III 62 GALNS 62 multicenter 62 Marketing Authorization Application MAA 62 bicifadine 62 masked placebo controlled 62 deforolimus 62 diabetic neuropathic pain 62 LibiGel Phase III 62 selective androgen receptor modulator 62 opioid induced bowel dysfunction 62 AEG# 62 PFO migraine 62 Veronate 62 oral prodrug 62 pralatrexate 62 aflibercept 62 MOZOBIL 62 Pivotal Phase III 62 lorvotuzumab mertansine 62 BRIM2 62 BCX# 62 pharmacokinetic PK 62 RDEA# 62 BLOOM DM 62 Fibrillex TM 62 Fx #A 62 clofarabine 62 Zenvia Phase III 62 GLP toxicology studies 62 CoFactor 62 Oglemilast 62 tolerability 62 PROPEL trial 62 PLK1 SNALP 62 CLIRS trial 62 Alzhemed TM 62 KRN# 62 blind randomized placebo 62 Amigal 62 Bicifadine 62 relapsing remitting multiple sclerosis 62 TMC# C# 62 PDX pralatrexate 62 dirucotide MBP# 62 cetrorelix 62 IIa clinical trial 62 NP2 Enkephalin 62 multicenter phase 62 Iluvien ® 62 trastuzumab DM1 T DM1 62 Zenvia ™ 62 PDE4 inhibitor 61 HGS# 61 confirmatory clinical 61 SNT MC# 61 obatoclax 61 perifosine 61 MEND CABG 61 Marqibo 61 phase III ACCLAIM 61 OvaRex ® MAb 61 OncoVEX GM CSF 61 PREOS R 61 rALLy trial 61 apaziquone 61 AZILECT R 61 relapsed refractory multiple myeloma 61 ITAX 61 celgosivir 61 New Drug Application 61 ganetespib 61 BLA filing 61 Anturol 61 Phase 1b dose escalation 61 IND submission 61 BAY #-# 61 Board DSMB 61 lintuzumab 61 Pivotal Trial 61 HuMax CD4 61 R#/MEM # 61 double blinded randomized 61 HCV protease inhibitor 61 IIa clinical 61 preclinical studies 61 PHX# 61 PEG Interferon lambda 61 European Sepsis Trial 61 cutaneous T cell 61 initiate Phase Ib 61 randomized controlled multicenter 61 EOquin TM 61 histone deacetylase HDAC inhibitor 61 Bronchitol 61 peginesatide 61 ToGA 61 PANVAC VF 61 Special Protocol Assessment 61 LUMINATE 61 ozarelix 61 AP# [003] 61 sunitinib malate 61 dimebon 61 aclidinium bromide 61 dose cohorts 61 ELND# 61 Mipomersen 61 ofatumumab HuMax CD# 61 Androxal TM 61 albinterferon alfa 2b 61 crofelemer 61 CHAMPION PCI 61 Medidur TM FA 61 Aryplase 61 NEBIDO 61 L BLP# 61 Phase IIB clinical 61 EFAPROXYN 61 Riquent 61 refractory gout 61 randomized Phase 2b 61 relapsed multiple myeloma 61 oral formulation 61 PS# [001] 61 rALLy clinical trial 61 ICA # 60 DR Cysteamine 60 Archexin 60 clevudine 60 sNDA submission 60 Augment Injectable 60 Gabapentin GR 60 PSN# [002] 60 ofatumumab 60 LUX Lung 60 QLT# 60 TOCOSOL Paclitaxel 60 controlled multicenter 60 pegloticase 60 SPIRIT III 60 investigational pan BCR 60 Allovectin 7 R 60 label multicenter 60 tamibarotene 60 ANTEGREN 60 TELINTRA 60 Allovectin 7 60 CDP# 60 Rezular 60 TBC# 60 tesmilifene 60 investigational antiplatelet agent 60 VNP#M 60 lorcaserin Phase 60 XIENCE V Stent System 60 tivozanib 60 randomized controlled clinical 60 bardoxolone 60 Exherin TM 60 Ostarine 60 Onalta ™ 60 ELACYT 60 ILLUMINATE 60 Phase 2a clinical trials 60 virus HCV protease inhibitor 60 ILUVIEN ® 60 severe hypercholesterolemia 60 velaglucerase alfa 60 Plicera 60 Ceplene 60 cangrelor 60 APPRAISE 60 hypoxia activated prodrug 60 Ixempra 60 Zelrix 60 DSMB 60 fostamatinib 60 IL# PE#QQR 60 Proxinium TM 60 Memryte 60 zanolimumab 60 phase IIIb 60 tremelimumab 60 oral calcitonin 60 Laquinimod 60 Virulizin R 60 Luveniq 60 ANCHOR trial 60 Troxatyl 60 unblind 60 Marketing Authorization Application 60 TLK# 60 multicentre randomized 60 enzastaurin 60 INCB# [002] 60 methylnaltrexone 60 mertansine 60 Nexavar sorafenib 60 APF# 60 label dose escalation 60 Plenaxis TM 60 Phase III Trial 60 ThermoDox R 60 ATryn R 60 vosaroxin 60 FavId 60 acyclovir Lauriad R 60 Stimuvax 60 Sym# 60 evaluating tivozanib 60 AzaSite Plus 60 Clinical Trial 60 ASA# 60 docetaxel Taxotere R 60 EndoTAG TM -1 60 dalbavancin 60 LE SN# 60 Diamyd ® 59 Viramidine 59 RG# [001] 59 PRT# 59 Elagolix 59 MEK inhibitor 59 elacytarabine 59 Phase #b/#a trial 59 Oncoscience AG 59 HuMax EGFr 59 IIb clinical trial 59 tramiprosate Alzhemed TM 59 Icatibant 59 TRISENOX 59 Stimuvax R 59 linaclotide 59 Shigamabs ® 59 generation PNP inhibitor 59 randomized multicenter Phase III 59 dose cohort 59 Soliris TM eculizumab 59 liprotamase 59 Pirfenidone 59 Phase III Clinical Trials 59 alogliptin 59 Phase #/#a trial 59 BST CarGel R 59 Allovectin 7 ® 59 CR# vcMMAE 59 tesetaxel 59 velafermin 59 Stedivaze 59 Cleviprex TM clevidipine 59 Civacir 59 eculizumab 59 GAMMAGARD 59 ATryn ® 59 Cloretazine 59 prospective multicenter 59 AeroLEF TM 59 belinostat 59 blinded randomized placebo controlled 59 Dalbavancin 59 NGX# 59 UPLYSO 59 metastatic hormone refractory 59 picoplatin 59 miconazole Lauriad ® 59 interferon gamma 1b 59 Pivotal Phase 59 eltrombopag 59 midstage clinical 59 luliconazole 59 vernakalant oral 59 CRMD# 59 ISIS # 59 MAXY alpha 59 neratinib 59 ALN TTR# 59 OHR/AVR# 59 Diabetic Macular Edema 59 StemEx R 59 blinatumomab 59 T DM1 59 sapacitabine 59 pharmacokinetics PK 59 leading oral taxane 59 Sular formulation 59 preclinical toxicology 59 HGS ETR1 59 Onrigin 59 initiate Phase 1b 59 PRE SURGE 59 Firazyr 59 SYMMETRY trial 59 cannabinor 59 TASKi2 59 blinded placebo controlled 59 pharmacokinetic studies 59 Anturol TM 59 LibiGel ® 59 Ocrelizumab 59 dyskinesia PD LID 59 Traficet EN 59 ABSORB trial 59 thorough QT 59 Biologics License Application BLA 59 ApoB SNALP 59 PXD# 59 Serada 59 MGCD# [001] 59 Sorafenib HCC Assessment 59 SCH # 59 Acetavance 59 XL# [003] 59 ADX# 59 initiate Phase 2b 59 confirmatory Phase 59 ataluren 59 RELOVAIR ™ 59 evaluating REVLIMID 59 ThermoDox ® 59 Phase III VISTA 59 pralatrexate injection 59 AVADO 59 Loramyc R 59 investigational oral 59 vidofludimus 59 IMC #B 59 OvaRex R 59 ecallantide 59 MEK inhibitor RDEA# 59 Phase 1b clinical trials 59 pomalidomide 59 octreotide implant 59 satraplatin 59 Phase IIb Trial 59 Myocet 59 Desmoteplase 59 CCR5 antagonist 59 Hematide 59 integrase inhibitor 59 Shigamabs R 59 assessing T DM1 59 OLpur TM H2H 59 StaphVAX 59 ABSORB clinical 59 regadenoson 59 SinuNase 59 eniluracil 59 oral methylnaltrexone 59 Phase 2b randomized 59 Onco TCS 59 lumiliximab 59 pradefovir 59 Phase III multicenter 59 brivaracetam 59 ENDEAVOR III 59 Gattex 59 APEX AMI trial 59 EDEMA3 59 Trofex 59 huC# DM4 58 Prednisporin TM 58 Rhucin 58 PRTX 58 trastuzumab emtansine T DM1 58 oral taxane 58 FOLOTYN 58 Phase III HEAT 58 NCCTG 58 anticancer compound 58 diarrhea predominant irritable 58 Trizytek 58 voreloxin 58 ZYBRESTAT fosbretabulin 58 TACI Ig 58 talactoferrin 58 PRECISE trial 58 Raptiva ® 58 ADAGIO study 58 HspE7 58 Zingo TM 58 afatinib 58 HCD# [002] 58 SinuNase TM 58 Biologics License Application 58 Darusentan 58 ONTARGET 58 ProLindac 58 Rhucin R 58 Prosaptide 58 microplasmin 58 omacetaxine mepesuccinate 58 II Clinical Trial 58 Nasulin 58 AZILECT ® 58 Daclizumab 58 Clolar 58 prospective randomized 58 unblinding 58 EchoCRT 58 Azedra TM 58 HCV SPRINT 58 Proellex TM 58 PROMACTA 58 TAXUS Element Stent System 58 bile duct tumor 58 TMC# [002] 58 ATL# [001] 58 MAGE A3 ASCI 58 SILENOR TM 58 intravenous formulation 58 ORENCIA ® 58 prGCD 58 alemtuzumab Campath 58 Initiate Phase 58 Fibrin Pad 58 vicriviroc 58 blind placebo controlled 58 Alocrest 58 Pimavanserin 58 MERLIN TIMI 58 Glybera R 58 PF # [002] 58 Topical Interferon Alpha 2b 58 LEP ETU 58 blind randomized 58 pharmacodynamics 58 Zybrestat 58 Phase III registrational 58 THALOMID 58 Annamycin 58 cathepsin K inhibitor 58 elagolix 58 CORLUX 58 ruxolitinib 58 multicenter placebo controlled 58 mitogen activated ERK kinase 58 unblinded 58 ancrod 58 Solazed 58 TRANSDUR Sufentanil 58 Xibrom QD 58 Preos 58 Viprinex 58 Azixa 58 APD# 58 ALTU 58 OncoVEX 58 dextromethorphan quinidine 58 VITAL Trial 58 sorafenib tablets 58 custirsen 58 Ereska 58 Entereg TM 58 RhuDex ® 58 ponatinib 58 multicenter randomized 58 NUVIGIL 58 pertuzumab 58 AEGR 58 Bezielle 58 Phase lll 58 targeted radiotherapeutic 58 Vicriviroc 58 hormone refractory prostate cancer 58 valopicitabine 58 ularitide 58 YONDELIS 58 darusentan 58 riociguat 58 arzoxifene 58 NVA# 58 IV APAP 58 GLPG# 58 AeroLEF 58 polymerase inhibitor 58 Tarvacin TM 58 ixabepilone 58 IPX# 58 RSD# 58 ENRICH trial 58 Vicinium TM 58 New Drug IND 58 romidepsin 58 Ophena TM 58 metastatic sarcomas 58 candidate AQ4N 58 AIR CF1 58 ridaforolimus 58 Triolex 58 Evoltra 58 Marketing Authorisation Application 58 thymalfasin 58 Investigational 58 FlutiformTM 58 Amoxicillin PULSYS 58 DermaVir Patch 58 eprotirome 58 Pivotal Study 58 LEVADEX 58 PRIMO CABG 58 IDX# 58 Staccato loxapine 58 Quinamed 58 omacetaxine 58 Nexavar ® 58 Dacogen 58 Dextofisopam 58 tezampanel 58 Aplidin 58 T Pred 58 Dyloject TM 58 Aclidinium 58 phase III isavuconazole 58 ulimorelin 58 Initiated Phase 58 Menerba 58 SUTENT ® 58 ONCONASE 58 lintuzumab SGN 58 Cellegesic 58 budesonide foam 58 R PEG uricase 58 active comparator 58 mGluR5 negative 58 Evoltra TM 58 RSR# 58 Tarceva TM 58 GED aPC 58 Keryx 58 Safinamide 58 ongoing Phase IIIb 58 Microplasmin 58 REOLYSIN ® 58 Rescula 58 trodusquemine 58 Flutiform ™ 58 UVIDEM 58 amrubicin 58 Aflibercept 58 Clolar ® 58 CRx 58 apricitabine 58 Lupuzor 58 Itopride 58 QNEXA 58 Cannabinor 58 trastuzumab DM1 58 maribavir 58 isavuconazole 58 Clonicel 58 multicenter randomized controlled 58 BioNumerik 58 PEP# [003] 58 Tarsa Therapeutics 58 PD LID 58 Relovair 58 PrevOnco 58 Parkinson disease levodopa induced 57 multicentre 57 Kynapid 57 XL# XL# XL# 57 betrixaban 57 Diabetic Macular Edema DME 57 relapsing multiple sclerosis 57 torezolid phosphate 57 senicapoc 57 StaphVAX R 57 multicentre randomized double 57 Locteron 57 Phase III TRIST 57 Locteron ® 57 Lung Rx 57 glucokinase activator 57 investigational humanized monoclonal antibody 57 hepatitis C HCV 57 LEUKINE 57 Nasdaq PGNX today 57 OncoGel 57 GSK# [002] 57 Ophena 57 nab paclitaxel 57 PRECiSE 57 initiated Phase Ib 57 Dyloject 57 enoximone capsules 57 LymphoStat B 57 incyclinide 57 multicenter study 57 Santhera 57 antibody MAb 57 PSMA ADC 57 Spiegelmer ® 57 Xanafide 57 cetuximab Erbitux 57 LymphoStat B TM 57 Cetrorelix 57 DU #b 57 Aurora kinase inhibitor 57 sNDA 57 OncoVex 57 CA4P 57 Insegia 57 refractory metastatic colorectal cancer 57 budesonide MMX 57 IPLEX 57 Diamyd R 57 HuMax CD# 57 PEARL SC 57 neurogenic orthostatic hypotension 57 investigational protease inhibitor 57 GATTEX 57 Tovaxin 57 oritavancin 57 edoxaban 57 ONCONASE R 57 rilonacept 57 dextofisopam 57 Tyrima 57 sodium Injection 57 Genasense ® 57 PrevOnco ™ 57 Prodarsan ® 57 PEG INTRON 57 Telcyta 57 Ambrisentan 57 Ketotransdel 57 monotherapy 57 oral iron chelator 57 Phase 2b monotherapy 57 visilizumab 57 multicenter prospective 57 Dapagliflozin 57 PEG SN# 57 ALN VSP 57 PNP inhibitor 57 Urocortin 2 57 Hyphanox 57 brentuximab vedotin SGN 57 humanized monoclonal antibody 57 dose dose escalation 57 HIV integrase inhibitor 57 Fortigel 57 PF # [001] 57 ostarine 57 CUSTOM III 57 JZP 57 pitavastatin 57 ACTEMRA 57 Carfilzomib 57 Cladribine Tablets 57 Reolysin 57 figitumumab 57 ketolide antibiotic 57 subcutaneously administered 57 teriflunomide 57 prospective randomized controlled 57 denufosol 57 StemEx 57 Anturol ® 57 Drug Eluting Stent System 57 interferon beta 1b 57 cell lymphoma CTCL 57 PRECISE Trial 57 MYDICAR 57 dexpramipexole 57 blinded randomized 57 Sunovion 57 ProSavin 57 Telavancin 57 elesclomol 57 oxypurinol 57 mapatumumab 57 Zolinza 57 faropenem medoxomil 57 albiglutide 57 fidaxomicin 57 LUVENIQ 57 Phase #/#a clinical 57 generation purine nucleoside 57 TG# [003] 57 AIR CF2 57 Randomized Phase 57 radiation sensitizer 57 Northera 57 cancer neuroendocrine tumor 57 registrational studies 57 symptomatic BPH 57 atacicept 57 REVLIMID lenalidomide 57 blind multicenter 57 HGS ETR2 57 telaprevir 57 bazedoxifene 57 cardio renal 57 refractory Hodgkin lymphoma 57 Ozarelix 57 Augment TM 57 tramiprosate ALZHEMED TM 57 Onconase 57 Clevudine 57 forodesine HCl 57 Panzem R NCD 57 AVN# [001] 57 CYT# 57 pirfenidone 57 VALOR trial 57 dacetuzumab 57 Orazol 57 Tesetaxel 57 Cimzia TM 57 Rhucin ® 57 investigational hepatitis C 57 novel histone deacetylase 57 Tanespimycin 57 tiapamil 57 phase III SIMPADICO 57 compound INCB# 57 velafermin belinostat 57 lymphoma CTCL 57 tramiprosate 57 ZADAXIN ® 57 pediatric glioma 57 TRO# 57 MONOVISC 57 vilazodone 57 SILENOR 57 MIRCERA 57 vandetanib 57 evaluating Actimmune 57 dacetuzumab SGN 57 LEVADEX ™ 57 Zerenex ™ 57 Neo Urinary Conduit 57 CIP TRAMADOL ER 57 Omnitarg 57 candidate Zenvia 57 IND Investigational New 57 huN# DM1 57 Application BLA 57 bortezomib Velcade 57 telbivudine 57 nebivolol 57 Tocosol Paclitaxel 57 RHUCIN 57 ceftaroline 57 Folotyn 57 Clinical Study 57 MyVax personalized immunotherapy 57 Factor VIIa 57 nalbuphine ER 57 BrachySil TM 57 tasimelteon 57 Iluvien 57 safety tolerability 57 metastatic castrate resistant 57 Rebif ® 57 novel oral anticoagulant 57 ThGRF 57 lucinactant 57 Tamibarotene 57 PREGNANT Study 57 MLN# 57 atrasentan 57 PROVENGE sipuleucel T 57 CRD5 57 JZP 6 57 CLARITY study 57 rindopepimut 57 methylnaltrexone bromide 57 EmbraceAC 57 L MTP PE 57 MyVax R 57 AA amyloidosis 57 liposomal formulation 57 PMA submission 57 prospective multicenter randomized 57 REPLAGAL 57 Torisel 57 nimotuzumab 57 Personalized Immunotherapy 57 orBec 57 subcutaneous RELISTOR 57 Teflaro 57 posaconazole 57 cutaneous T 57 Phase III metastatic melanoma 57 RE LY ® 57 Fast Track designation 57 Celacade TM technology 57 Hepatitis C HCV 57 Ventavis 57 Ferumoxytol 57 IMC A# 56 seliciclib CYC# 56 candidates bavituximab 56 Premarket Approval PMA 56 ZoMaxx 56 HepeX B 56 Fampridine SR 56 faropenem 56 ALN RSV# 56 histamine dihydrochloride 56 Acapodene 56 DSMB recommended 56 Phase IIb Clinical Trial 56 rhC1INH 56 Nuvion 56 Prodarsan 56 Onalta 56 Prolacria 56 Zalbin 56 Marketing Authorisation Application MAA 56 refractory CLL